Literature DB >> 26278104

An orthotopic xenograft model with survival hindlimb amputation allows investigation of the effect of tumor microenvironment on sarcoma metastasis.

Seth D Goldstein1, Masanori Hayashi1, Catherine M Albert1, Kyle W Jackson1, David M Loeb2.   

Abstract

Overall survival rates for pediatric high-grade sarcoma have improved greatly in the past few decades, but prevention and treatment of distant metastasis remain the most compelling problems facing these patients. Traditional preclinical mouse models have not proven adequate to study the biology and treatment of spontaneous distant sarcoma metastasis. To address this deficit, we developed an orthotopic implantation/amputation model in which patient-derived sarcoma xenografts are surgically implanted into mouse hindlimbs, allowed to grow, then subsequently amputated and the animals observed for development of metastases. NOD/SCID/IL-2Rγ-null mice were implanted with either histologically intact high grade sarcoma patient-derived xenografts or cell lines in the pretibial space and affected limbs were amputated after tumor growth. In contrast to subcutaneous flank tumors, we were able to consistently detect spontaneous distant spread of the tumors using our model. Metastases were seen in 27-90 % of animals, depending on the xenograft, and were repeatable and predictable. We also demonstrate the utility of this model for studying the biology of metastasis and present preliminary new insights suggesting the role of arginine metabolism and macrophage phenotype polarization in creating a tumor microenvironment that facilitates metastasis. Subcutaneous tumors express more arginase than inducible nitric oxide synthase and demonstrate significant macrophage infiltration, whereas orthotopic tumors express similar amounts of inducible nitric oxide synthase and arginase and have only a scant macrophage infiltrate. Thus, we present a model of spontaneous distant sarcoma metastasis that mimics the clinical situation and is amenable to studying the biology of the entire metastatic cascade.

Entities:  

Keywords:  Animal model; Arginase; Ewing sarcoma; Metastasis; Osteosarcoma; Rhabdomyosarcoma

Mesh:

Year:  2015        PMID: 26278104     DOI: 10.1007/s10585-015-9738-x

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  37 in total

1.  Experimental pulmonary sarcoma metastases in athymic nude mice.

Authors:  T C Chao; J A Greager
Journal:  J Surg Oncol       Date:  1997-06       Impact factor: 3.454

Review 2.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

Review 3.  Nitric oxide and metastatic cell behaviour.

Authors:  Emma L Williams; Mustafa B A Djamgoz
Journal:  Bioessays       Date:  2005-12       Impact factor: 4.345

Review 4.  Challenges and opportunities in childhood cancer drug development.

Authors:  Robin E Norris; Peter C Adamson
Journal:  Nat Rev Cancer       Date:  2012-10-11       Impact factor: 60.716

5.  An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential.

Authors:  C Khanna; J Prehn; C Yeung; J Caylor; M Tsokos; L Helman
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

6.  Development of mature and functional human myeloid subsets in hematopoietic stem cell-engrafted NOD/SCID/IL2rγKO mice.

Authors:  Satoshi Tanaka; Yoriko Saito; Jun Kunisawa; Yosuke Kurashima; Taichi Wake; Nahoko Suzuki; Leonard D Shultz; Hiroshi Kiyono; Fumihiko Ishikawa
Journal:  J Immunol       Date:  2012-05-18       Impact factor: 5.422

7.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.

Authors:  Mamoru Ito; Hidefumi Hiramatsu; Kimio Kobayashi; Kazutomo Suzue; Mariko Kawahata; Kyoji Hioki; Yoshito Ueyama; Yoshio Koyanagi; Kazuo Sugamura; Kohichiro Tsuji; Toshio Heike; Tatsutoshi Nakahata
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

8.  Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma.

Authors:  Eisuke Kobayashi; Mari Masuda; Robert Nakayama; Hitoshi Ichikawa; Reiko Satow; Miki Shitashige; Kazufumi Honda; Umio Yamaguchi; Ayako Shoji; Naobumi Tochigi; Hideo Morioka; Yoshiaki Toyama; Setsuo Hirohashi; Akira Kawai; Tesshi Yamada
Journal:  Mol Cancer Ther       Date:  2010-02-16       Impact factor: 6.261

Review 9.  Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved.

Authors:  Robert S Kerbel
Journal:  Cancer Biol Ther       Date:  2003 Jul-Aug       Impact factor: 4.742

Review 10.  Functions of arginase isoforms in macrophage inflammatory responses: impact on cardiovascular diseases and metabolic disorders.

Authors:  Zhihong Yang; Xiu-Fen Ming
Journal:  Front Immunol       Date:  2014-10-27       Impact factor: 7.561

View more
  12 in total

1.  Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA.

Authors:  Masanori Hayashi; David Chu; Christian F Meyer; Nicolas J Llosa; Gregory McCarty; Carol D Morris; Adam S Levin; Jean-Paul Wolinsky; Catherine M Albert; Diana A Steppan; Ben Ho Park; David M Loeb
Journal:  Cancer       Date:  2016-06-28       Impact factor: 6.860

2.  Genome-Informed Targeted Therapy for Osteosarcoma.

Authors:  Leanne C Sayles; Marcus R Breese; Amanda L Koehne; Stanley G Leung; Alex G Lee; Heng-Yi Liu; Aviv Spillinger; Avanthi T Shah; Bogdan Tanasa; Krystal Straessler; Florette K Hazard; Sheri L Spunt; Neyssa Marina; Grace E Kim; Soo-Jin Cho; Raffi S Avedian; David G Mohler; Mi-Ok Kim; Steven G DuBois; Douglas S Hawkins; E Alejandro Sweet-Cordero
Journal:  Cancer Discov       Date:  2018-09-28       Impact factor: 39.397

Review 3.  Canine and murine models of osteosarcoma.

Authors:  Jessica Beck; Ling Ren; Shan Huang; Erika Berger; Kathleen Bardales; Joshua Mannheimer; Christina Mazcko; Amy LeBlanc
Journal:  Vet Pathol       Date:  2022-03-26       Impact factor: 3.157

4.  The Ewing Sarcoma Secretome and Its Response to Activation of Wnt/beta-catenin Signaling.

Authors:  Allegra G Hawkins; Venkatesha Basrur; Felipe da Veiga Leprevost; Elisabeth Pedersen; Colin Sperring; Alexey I Nesvizhskii; Elizabeth R Lawlor
Journal:  Mol Cell Proteomics       Date:  2018-01-31       Impact factor: 5.911

5.  Intratibial Injection Causes Direct Pulmonary Seeding of Osteosarcoma Cells and Is Not a Spontaneous Model of Metastasis: A Mouse Osteosarcoma Model.

Authors:  Caroline Maloney; Morris C Edelman; Michelle P Kallis; Samuel Z Soffer; Marc Symons; Bettie M Steinberg
Journal:  Clin Orthop Relat Res       Date:  2018-07       Impact factor: 4.176

6.  Polyphyllin I suppresses human osteosarcoma growth by inactivation of Wnt/β-catenin pathway in vitro and in vivo.

Authors:  Junli Chang; Yimian Li; Xianyang Wang; Shaopu Hu; Hongshen Wang; Qi Shi; Yongjun Wang; Yanping Yang
Journal:  Sci Rep       Date:  2017-08-08       Impact factor: 4.379

Review 7.  Patient-derived xenograft models in musculoskeletal malignancies.

Authors:  Wan Lu; Tu Chao; Chen Ruiqi; Su Juan; Li Zhihong
Journal:  J Transl Med       Date:  2018-04-23       Impact factor: 5.531

8.  Isolation of circulating tumor cells in a preclinical model of osteosarcoma: Effect of chemotherapy.

Authors:  Antoine Chalopin; Marta Tellez-Gabriel; Hannah K Brown; François Vallette; Marie-Françoise Heymann; Francois Gouin; Dominique Heymann
Journal:  J Bone Oncol       Date:  2018-07-26       Impact factor: 4.072

9.  A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model.

Authors:  Seth D Goldstein; Matteo Trucco; Wendy Bautista Guzman; Masanori Hayashi; David M Loeb
Journal:  Oncotarget       Date:  2016-04-19

10.  Inhibition of porcupine prolongs metastasis free survival in a mouse xenograft model of Ewing sarcoma.

Authors:  Masanori Hayashi; Alissa Baker; Seth D Goldstein; Catherine M Albert; Kyle W Jackson; Gregory McCarty; Ulf D Kahlert; David M Loeb
Journal:  Oncotarget       Date:  2017-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.